07-08-2026 21:55 via medpagetoday.com

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

(MedPage Today) -- Liposomal daunorubicin and cytarabine (Vyxeos) didn't hold up to standard daunorubicin/cytarabine induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML), a phase III trial from the Children...
Read more »

Medical Industry news



Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?
Can 'Ferritin Face' Signal Underlying Anemia? Hematologists Weigh In
Genomic Newborn Screening Could Identify Childhood Cancer Predisposition
What's Going on With Fall COVID and Flu Shots?
A Looksmaxxing App Promised I Could Be Hot in 90 Days
What Pet Was Linked to a Brain Disorder?
'The Pitt' Season 3 Teaser; Gain-of-Function Debate; Advice for CDC's New Chief
What to Know About a Dispute Between a Couple, Their Surrogate, and Texas Courts
Doctor Found Dead; AMA Sued Over Billing Codes; CMS Engaged in Voter Suppression?
FDA Approves First CELMoD Drug for Multiple Myeloma
Luigi Mangione Expected to Plead Guilty in UnitedHealthcare CEO Killing, Source Says
Preoperative GLP-1s Don't Diminish Bariatric Surgery Results, Study Suggests
Researchers Try to Tie Cannabis to Irregular Heartbeats, Opposite Turns Out True
JAK Inhibitor Might Be the Most Effective One Yet for Severe Alopecia
Desktop versie